The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study

dc.contributor.author Sahuquillo-Torralba, Antonio
dc.contributor.author Ferran Farrés, Marta
dc.contributor.author García-Doval, Ignacio
dc.contributor.author Biobadaderm Study Group
dc.date.accessioned 2020-04-22T06:53:57Z
dc.date.issued 2020
dc.description.abstract Biobadaderm is a multicenter prospective cohort that was created to evaluate the safety of systemic therapy for psoriasis patients.2 Once a year, reports are created. In 2018, a signal regarding symptomatic urinary tract infection (UTI) was detected.
dc.format.mimetype application/pdf
dc.identifier.citation Sahuquillo-Torralba A, Carretero G, Rivera R, Ferrándiz C, Daudén-Tello E, de la Cueva P, et al. The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study. J Am Acad Dermatol. 2020 Mar; 82(3):738-41. DOI: 10.1016/j.jaad.2019.07.028
dc.identifier.doi http://dx.doi.org/10.1016/j.jaad.2019.07.028
dc.identifier.issn 0190-9622
dc.identifier.uri http://hdl.handle.net/10230/44301
dc.language.iso eng
dc.publisher Elsevier
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.subject.other Aparell urinari -- Infeccions
dc.subject.other Psoriasi
dc.title The risk of urinary tract infections in patients with psoriasis on systemic medications in biobadaderm registry: a prospective cohort study
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/acceptedVersion

Col·leccions